- In patients with aggressive lymphomas, cachexia offers different prognostic utility in men vs women and may be linked to specific metabolic and immune markers.
Why this matters
- Cachexia affects 60%-80% of patients with cancer and is believed to be an anabolic state resulting from changes in metabolism supporting tumor proliferation/growth.
- Study to investigate associations between cachexia and outcomes in 109 patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL).
- Funding: None disclosed.
- In males:
- 5.4 months median PFS with sarcopenia vs 72.3 months without (P<.0005>
- 30.2 months median OS with sarcopenia vs not reached (NR) without (P=.02).
- 21.6 months median OS with adipopenia vs NR without (P=.036).
- Sarcopenia yielded nonsignificant trend for extended OS (P=.078).
- No significant association between adipopenia and reduced OS (P=.118).
- Glucose metabolism pathway:
- Insulin-like growth factor proteins 6 and 1: P=.04 and .02, respectively.
- Inflammatory pathway:
- Lymphotoxin-like inducible protein that competes with glycoprotein D for herpesvirus entry on T-cells (LIGHT): P=.005.
- Energy expenditure: P=.004.
- Limited sample size.